Seeking Alpha · 1 min read

Amgen drops on Novartis trial setback for heart therapy; BMO downgrades

Amgen drops on Novartis trial setback for heart therapy; BMO downgrades

This is a summary aggregated from Seeking Alpha. Read the complete article on the original site:

Read full article at Seeking Alpha

More Health & Medical News